Tahsim Anwar: A Six-Year Analysis of Adverse Events in Therapeutic Apheresis
Tahsim Anwar, Assistant Professor at Institute of Medical Sciences and Sum Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Therapeutic Apheresis and Dialysis, adding:
“New publication alert!
Our paper ‘Risk Factor Analysis of Adverse Events in Therapeutic Apheresis: A Tertiary Care Center Perspective From Eastern India’ is now published in Therapeutic Apheresis and Dialysis.
Therapeutic apheresis is life-saving, but it carries risks. We looked at 348 procedures in 127 patients over 6 years at the Department of Transfusion Medicine, AIIMS Bhubaneswar.
What we found
- Adverse events occurred in 54 procedures (15.5%) and in 45 patients (35.4%)
- Hypotension was the most common event, followed by allergic reactions and febrile non-haemolytic reactions
- Citrate toxicity was rare (0.6% of procedures), likely because of continuous calcium replacement
- Most events were mild (Grade I–II). There was one Grade III event and no deaths
- Key risk factors: the number of procedures per patient (5 or more sessions in TPE), neurological disease, and younger age
Why it matters
Closer monitoring and tailored preventive strategies, especially for patients needing repeated sessions, can make apheresis safer. This is relevant in resource-limited settings, where albumin is not always affordable and FFP is often the replacement fluid.
Thank you Satya Prakash sir, Somnath Mukherjee sir, and all my co-authors for this work.”
Title: Risk Factor Analysis of Adverse Events in Therapeutic Apheresis: A Tertiary Care Center Perspective From Eastern India
Authors: Satya Prakash, Tahsim Anwar, Ansuman Sahu, Debasish Mishra, Noufal Hussain R., Somnath Mukherjee
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 25, 2026, 19:37William Wallace: More than 1 in 3 People with Parkinson’s Were Low in B6
-
Oct 25, 2026, 19:36Andrés Felipe Escobar González: Individualized Treatment Strategies for HMB in BDUC
-
Oct 25, 2026, 19:34Christophe Nougier: Returning to Burundi for the WFH-Supported Twinning Project
-
Oct 25, 2026, 19:29Bogda Koczwara: Pre-Existing and New CVD in Patients With Cancer Are Associated With Higher Mortality
-
Oct 25, 2026, 19:23Özlem Turan: Advancing Care for Women and Girls With Bleeding Disorders at the European Parliament
-
Oct 25, 2026, 18:36James P. Crowley: Gene Inactivation and Targeted Gene Repair as Two Approaches to CRISPR Gene Editing
-
Oct 25, 2026, 17:43Jan Sloves: Femoral Vein Aneurysm and Chronic Venous Obstruction
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist